{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:32:32Z","timestamp":1770780752422,"version":"3.50.0"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vatiquinone is a small\u2010molecule inhibitor of 15\u2010lipoxygenase in phase 3 development for patients with mitochondrial disease and Friedreich ataxia. The objective of this analysis was to determine the effect of vatiquinone on the pharmacokinetic profile of rosuvastatin, a breast cancer resistance protein substrate. In vitro investigations demonstrated potential inhibition of BCRP by vatiquinone (half maximal inhibitory concentration, 3.8 \u00b5M). An open\u2010label, fixed\u2010sequence drug\u2010drug interaction study in healthy volunteers was conducted to determine the clinical relevance of this finding. Subjects received a single dose of 20\u2010mg rosuvastatin followed by a 7\u2010day washout. On days 8 through 14, subjects received 400\u00a0mg of vatiquinone 3 times daily. On day\u00a012, subjects concomitantly received a single dose of 20\u2010mg rosuvastatin. The geometric mean ratio for maximum plasma concentration was 77.8%; however, the rosuvastatin disposition phase appeared unaffected. The geometric mean ratios for the area under the plasma concentration\u2013time curve from time 0 to time t and from time 0 to infinity were 103.2% and 99.9%, respectively. Mean rosuvastatin apparent elimination half\u2010life was similar between treatment groups. These results demonstrate that vatiquinone has no clinically relevant effect on the pharmacokinetics of rosuvastatin.<\/jats:p>","DOI":"10.1002\/cpdd.1199","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T17:12:27Z","timestamp":1670433147000},"page":"279-286","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Drug\u2010Drug Interaction Between Vatiquinone, a 15\u2010Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein Substrate"],"prefix":"10.1002","volume":"12","author":[{"given":"Lucy","family":"Lee","sequence":"first","affiliation":[{"name":"PTC Therapeutics, Inc.  South Plainfield New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Murase","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc.  South Plainfield New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyuan","family":"Ma","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc.  South Plainfield New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Thoolen","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc.  South Plainfield New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.10.009"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1989.tb09150.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2001.00922.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.09.023"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2013.03.011"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2015.01.005"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2017.01.004"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2018-0013"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03393-0"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9668-6"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.01.018"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2021.2010287"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.013"},{"issue":"1","key":"e_1_2_8_15_1","first-page":"46","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach RS","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3028"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.86"},{"issue":"8","key":"e_1_2_8_18_1","first-page":"3458","article-title":"Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues","volume":"61","author":"Maliepaard M","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.066795"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.116"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1199","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1199","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T16:22:12Z","timestamp":1692375732000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/cpdd.1199"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1199","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,7]]},"assertion":[{"value":"2022-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}